

---

## SenzaGen H2 - Continued growth and aligned with our expectations

Redeye provides an update in relation to SenzaGen's H2 2023 report. We argue the report was solid and aligned with our expectations, where sales came in at SEK26.3m and EBIT at SEK-10.0m. We have made some estimate changes, resulting in an updated fair value range. However, our base case remains at SEK20.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

**SenzaGen H2 - Continued growth and aligned with our expectations**